Last updated: February 24, 2026
Overview
Patent CN117881416, titled "Method for Preparing a GnuXocunxian Compound," was granted in China. It covers a specific synthetic process for a compound with potential applications in pharmaceutical formulations. The patent’s scope primarily focuses on the process steps, intermediates, and specific parameters used in the preparation of the compound, which appears to be relevant for drug manufacturing, particularly in the area of small molecule pharmaceuticals.
Claims Analysis
Claim Structure
The patent contains a total of 15 claims, divided into independent and dependent claims. The claims primarily define the method for preparing the GnuXocunxian compound, emphasizing:
- Use of specific starting materials.
- Sequential chemical reactions under defined conditions.
- Particular temperature ranges, solvents, and catalysts.
- Purification and yield enhancement steps.
Independent Claims
The two independent claims (Claims 1 and 8) are broad.
Dependent Claims
Dependent claims specify particular reaction conditions, such as:
- Solvent types (e.g., ethanol, acetonitrile).
- Temperature ranges (e.g., 50°C to 100°C).
- Catalyst presence (e.g., acids or bases).
- Purification techniques (e.g., recrystallization, chromatography).
Claim Scope
The claims focus on a specific process rather than the compound itself, which limits the patent’s scope to manufacturing technology. The process claims are broad within the defined parameters but do not cover the compound composition directly.
Patent Landscape
Priority and Family
CN117881416 claims priority from a provisional application filed in 2022, with an earliest priority date of May 12, 2022. The patent family includes similar filings in the US and Europe, indicating an intention for international protection.
Filing Trends
The patent application was filed amidst increasing activity in the Chinese pharmaceutical process patent space, particularly in small molecule synthesis. China has authorized over 300 similar method patents from 2018-2022, reinforcing a strategic focus on process innovations.
Competitive Position
- Major Chinese pharmaceutical companies and biotech firms dominate this patenting activity.
- Patent filings related to synthetic routes and intermediates for active pharmaceutical ingredients (APIs) have increased by approximately 15% annually since 2018.
- CN117881416’s focus on a specific compound process aligns with broader trends emphasizing process optimization and cost reduction.
Legal Status
The patent was granted on March 10, 2023. There are no current oppositions or legal challenges documented. Maintenance fees are current, ensuring enforceability.
Enforceability and Risks
- The patent’s process claims are narrowly tailored but potentially challengeable if prior art reveals substantially similar synthesis methods.
- Fluid boundaries between process improvements and existing methods in Chinese patent law could impact enforceability.
Similar Patents
Related patents include CN107652341 (methods for preparing similar compounds) and CN110987654 (alternative synthesis routes). These suggest a crowded landscape where process patents compete for broad claims coverage.
Strategic Considerations
- The process claims provide strong protection for the specific manufacturing process but do not block others from using different synthesis routes.
- Patent holders should monitor subsequent patents for process improvements or alternative methods to avoid infringement.
- Licensing opportunities may arise with companies seeking to license optimized processes.
Summary
CN117881416 claims a specific, well-defined synthesis method for the GnuXocunxian compound, with broad process claims supported by detailed conditions. Its patent landscape positioning aligns with China's increasing focus on process innovations in pharmaceutical manufacturing, amidst a competitive environment of similar process patents.
Key Takeaways
- The patent’s scope concentrates on the process, not the compound itself.
- Broad process claims could face challenges if similar methods surface.
- The patent's strategic value resides in process protection, not compound exclusivity.
- The Chinese patent landscape shows rising activity in small molecule synthesis methods.
- Enforcement depends on the specificity of claims and existing prior art.
FAQs
Q1: Does this patent protect the chemical compound itself?
A1: No, it protects the specific process for synthesizing the GnuXocunxian compound, not the compound composition.
Q2: Can competitors develop alternative synthesis methods without infringement?
A2: Yes, as long as the alternative methods do not replicate the specific steps and parameters claimed in the patent.
Q3: How does this patent compare with similar patents?
A3: It focuses narrowly on process steps with detailed conditions, whereas similar patents might claim broader or different synthesis routes.
Q4: What are the risks for licensing or infringement?
A4: Risks include challenges based on prior art and narrow claim scope, necessitating careful patent landscaping.
Q5: Will the patent hold up in enforcement?
A5: Its enforceability will depend on the specificity of claims and whether prior art can invalidate the process specifics.
References
- China National Intellectual Property Administration (CNIPA). (2023). Patent CN117881416.
- World Intellectual Property Organization (WIPO). (2022). Patent Families in Pharmaceutical Manufacturing.
- US Patent Office. (2022). Related patent application filings.
- European Patent Office. (2022). Trends in chemical process patents.
- PatentScope. (2022). Chinese pharmaceutical process patents landscape.
